Traditional factors
History, blood pressure, diabetes, obesity, cholesterol and other clinical data remain at the center of the evaluation.
Cardiovascular prevention
Understand cardiovascular risk before symptoms.
CardioRisk combines history, clinical factors, laboratory tests and genetic variants to make risk assessment more individual and support the conversation with your doctor.
- Assessment
- Clinical, laboratory and genetics
- Sample
- Mouth swab or blood
- Result
- Care-oriented report
- Support
- Specialized team
Personalized prevention
An integrated reading of risk.
Cardiovascular risk results from the interaction between genetics, age, family history, clinical conditions and habits. CardioRisk organizes this information to support an individualized monitoring plan.
Inherited predisposition
Monogenic variants and risk scores can add information about cardiovascular predispositions.
Contextualized result
The report brings together the relevant findings for discussion with the doctor, without replacing the clinical assessment.
Clinical indication
When to consider CardioRisk?
The indication must consider age, history, previous tests and the clinical question. The result should not be interpreted in isolation.
01
Adults between 40 and 74 years old
Range in which the risk tends to increase, especially when there is hypertension, diabetes, obesity or other comorbidities.
02
Relevant family history
Heart attack, stroke, arrhythmias, cardiomyopathies or other cardiovascular diseases in close relatives.
03
Heart condition without defined cause
Symptoms or changes in which a hereditary condition may contribute to the diagnostic investigation.
04
Multiple risk factors
Complex situations where integrating genetics and clinical data can refine stratification.
05
Family planning
Families who want to understand the possibility of passing on hereditary heart conditions.
06
Cardiovascular research
Clinical projects that investigate the genetic contribution to cardiovascular disease, according to a specific protocol.
Risk stratification
Genetic information can anticipate risk identification.
In a study with more than 40,000 NHS participants, combining a polygenic score with QRISK2 increased the identification of people aged 40 to 54 classified as having high cardiovascular risk. The individual benefit depends on the clinical context and the population analyzed.
26%
Proportion identified by the clinical method presented in the study.
38,4%
Proportion identified after incorporating the polygenic score.
47,7%
Relative increase in identification in the analyzed section; does not represent an individual reduction in events.
Post-report follow-up
Science evolves. The interpretation of a variant may also evolve.
All NeoGenomica tests include Infinity VUS for variants of uncertain significance that are reported.
Your result monitored over time
A variant of uncertain significance, or VUS, is a finding for which the available evidence does not yet allow us to conclude whether it is related to the disease. Infinity VUS monitors classification updates even after the report is issued.
-
01 · Monitor
Periodically compares reported VUS with new evidence and classifications.
-
02 · Review
A material change is forwarded for expert review before any communication.
-
03 · Update
When the reclassification is confirmed and applicable to the case, the responsible team is notified and the report can be updated.
Test day
From assessment to care plan.
An integrated flow to combine clinical, laboratory and genetic data.
-
01
Clinical assessment
Forms gather history, risk factors and laboratory results.
-
02
Sample collection
Mouth swab or blood, as directed by the team.
-
03
Integrated analytics
Clinical, laboratory and genetic data are evaluated together.
-
04
Report and guidance
The result supports medical discussion and follow-up planning.
The release deadline must be confirmed at the time of the request.
Interpretation
An organized result for the query.
The report presents the main findings, lists the risk categories assessed and offers support for medical monitoring.
- Summary of relevant clinical and genetic findings.
- Analysis by category of cardiovascular disease.
- Recommendations for discussion with the doctor and, when applicable, family members.
Frequently asked questions
Before ordering.
Does CardioRisk replace cardiological evaluation?+
No. The test adds genetic information to the evaluation of clinical and laboratory factors. Interpretation and any care decisions should be made with the doctor.
What can the result show?+
The report can bring together monogenic predispositions, risk scores and their relationship with clinical information, depending on the contracted scope and the quality of the data received.
How is sample collection done?+
The sample can be a mouth swab or blood. The team informs you of the appropriate material and guides sample collection and shipping.
Does a high genetic risk mean I will have the disease?+
Not necessarily. Predisposition is not diagnosis. Age, habits, other conditions and treatments also influence risk and need to be considered.
Could the result be relevant to family members?+
Hereditary findings may justify evaluation of family members. When this occurs, the report will guide the discussion with the assistant team.
Next step
Bring more context to your cardiovascular prevention.
Talk to the team to understand the scope, sample collection and how to integrate the result into medical monitoring.
Catalog information
Technical data of CardioRisk
Genetic assessment applied to cardiovascular risk and personalized prevention.
- Applications
- Personalized prevention, Cardiovascular risk
- Accepted samples
- peripheral blood, Mouth swab (preferred), DNA extraído
- Estimated deadline
- Deadline subject to confirmation by the technical team.
- Methodology
- Integrated assessment of clinical, laboratory and genetic data.
- Analytical scope
- Traditional factors, monogenic variants and cardiovascular risk scores, contextualized in the report.
- Medical request
- Required
Requirements
History, risk factors and laboratory results; the indication considers age, history, previous tests and clinical question.
Limitations
The result should not be interpreted in isolation and does not replace clinical evaluation. The deadline must be confirmed in the request.
